Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CASP6 | P55212 | 1/20 | 0.98 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.41 |
| ▸ | HTR3B | O95264 | 2/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alosetron SCHEMBL29377019 | 1.00 | KCNH2 (1.00) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL29387635 | 0.99 | CASP6 (1.00) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL806 | 0.99 | CASP6 (1.00) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL635233 | 0.98 | KCNH2 (0.96) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL850 | 0.95 | KCNH2 (0.90) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| SCHEMBL837 | 0.94 | KCNH2 (0.88) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL13345838 | 0.93 | KCNH2 (0.86) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL1046 | 0.92 | KCNH2 (0.85) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL1045 | 0.92 | KCNH2 (0.85) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL13345845 | 0.90 | KCNH2 (0.81) | KCNH2HTR3ACYP3A4CYP1A2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6088 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4705511-A1 | DNA METHYLATION-BASED ALGORITHM TO DIAGNOSE IRRITABLE BOWEL SYNDROME AND OTHER GI CONDITIONS | The Regents of the University of California (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4683627-A1 | AMELIORATION OF DRUG-DRUG INTERACTIONS | Ontrack Therapeutics Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| EP-4658240-A2 | PHARMACEUTICAL COMPOSITIONS FOR NASAL DELIVERY | Therakind Limited (GB) | 2025-12-10 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| CN-120189416-A | Method for treating bile acid diarrhea | 加利福尼亚大学董事会 | 2025-06-24 | — | — | CN | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-5360800-A | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | GLAXO GROUP LIMITED (GB) | 1994-11-01 | — | — | US | claimed |
| EP-0306323-B1 | Lactam derivatives | GLAXO GROUP LTD (GB) | 1994-09-21 | — | — | EP | claimed |
| US-5342627-A | Controlled release device | GLAXO CANADA INC. (CA) | 1994-08-30 | — | — | US | claimed |
| US-5276050-A | Administering for treatment of bulemia or seasonal affective disorder | GLAXO GROUP LIMITED (GB) | 1994-01-04 | — | — | US | claimed |
| US-5229407-A | Administering to humans or animals for treatment of cognitive disorders | GLAXO GROUP LIMITED (GB) | 1993-07-20 | — | — | US | claimed |
| US-5225407-A | Cognition activators | GLAXO GROUP LIMITED (GB) | 1993-07-06 | — | — | US | claimed |
| US-5221687-A | Antidepressants | GLAXO GROUP LIMITED (GB) | 1993-06-22 | — | — | US | claimed |
| EP-0458624-A1 | Process for the preparation of lactam derivatives | GLAXO GROUP LIMITED (GB) | 1991-11-27 | — | — | EP | claimed |
| EP-0450757-A2 | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood | GLAXO GROUP LIMITED (GB) | 1991-10-09 | — | — | EP | claimed |
| EP-0411901-A2 | Treatment of conditions involving excessive eating | GLAXO GROUP LIMITED (GB) | 1991-02-06 | — | — | EP | claimed |